Addressing barriers that inhibit value-based contracts

With 56 new medicines approved by the U.S. Food and Drug Administration (FDA) in 2019 and over 8,000 medicines in development around the globe, innovative medicines are transforming the way we treat...
Read More
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....
Read More
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Setting the record straight on international reference pricing

There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...
Read More
Fact Check: How the Part B International Pricing Index model threatens patient access

Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around about...
Read More
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

A new analysis from Xcenda found that if Medicaid were to use one-size-fits-all value assessments like the Institute for Clinical and Economic Review’s (ICER) framework as the basis for accessing a...
Read More
PhRMA comments to administration on Medicare Part D proposed rule

Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the CMS proposed rule, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and...
Read More
ICYMI: New study reinforces dangers of proposed IPI model

Stakeholder after stakeholder has raised concerns that the Department of Health and Human Services’ proposed International Pricing Index (IPI) Model would put patient access to medicines in Medicare...
Read More
Groups sound the alarm on administration’s new Part B proposal

Last month, the Administration announced a dangerous new proposal, the International Pricing Index Model, that would upend the delivery of Medicare Part B medicines. As PhRMA President and CEO...
Read More
4 things you need to know about the administration’s latest Part B proposal

The Department of Health and Human Services (HHS) recently released an Advance Notice of Proposed Rulemaking regarding Medicare Part B that puts patient access to medicines and Part B at risk....
Read More